ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Completed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.

Key facts

Study ID

NCT00014183

Run by

University of Maryland, Baltimore

Starts

2001-01-01

Expected to finish

2005-08-01

Last updated by the study team

2019-11-07

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Veterans Affairs Medical Center - Baltimore — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.